Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

Tapestry: Addition of TGF-β and PDL-1 Inhibition to Definitive Chemoradiation in Esophageal Squamous Cell Carcinoma (TAPESTRY)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT04595149
Recruitment Status : Recruiting
First Posted : October 20, 2020
Last Update Posted : January 19, 2021
Information provided by (Responsible Party):
H.W.M. van Laarhoven, Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

Brief Summary:
The outcome of irresectable oesophaguscancer is poor, despite the fact that curative treatment with definitive chemoradiation is possible. The outcome of treatment can possibly be improved by combining chemoradiation with immunotherapy such as bintrafusp alfa, a combined TGF-β and PD-L1 inhibitor. In this study investigators investigate the feasibility of combining bintrafusp alfa with definitive chemoradiation in patients with irresectable squamous cell carcinoma of the esophagus.

Condition or disease Intervention/treatment Phase
Neoplasm, Esophagus Malignant Esophagus Tumor Neoplasm, Esophageal Combination Product: Bintrafusp alfa Phase 2

Detailed Description:

This is a non-randomized feasibility study in which patients with esophageal squamous cell carcinoma receive bintrafusp alfa (B), combined with paclitaxel (P), carboplatin (C), and radiation (RT). For safety reasons the first ten patients will be treated in a maximum of four selected hospitals. If no unexpected safety signals occur, the study will start in all participating centers.

Paclitaxel 50 mg/m2 and Carboplatin AUC = 2 will be given by intravenous infusion on days 1, 8, 15, 22, 29, and 36. External beam radiotherapy will be delivered to a total dose of 50.4 Gy in 28 fractions of 1.8 Gy, 5 fractions per week, starting the first day of the first cycle of chemotherapy (see below for details on radiation technique).

Bintrafusp alfa will be given iv every three weeks on day 1, 22, and 43 at a dose of 2400 mg.

Wk 1 Wk 2 Wk 3 Wk 4 Wk 5 Wk 6 Wk 7 Day 1 Day 8 Day 15 Day 22 Day 29 Day 36 Day 43 __________________________________________________

P P P P P P C C C C C C B B B RTx5 RTx5 RTx5 RTx5 RTx5 RTx3

__________________________________________________ P = paclitaxel; C = carboplatin, B = bintrafusp alfa RT = radiotherapy

Feasibility of this treatment strategy is the main focus of this study. In this study feasibility is defined as ≥80% of patients completing two cycles (of in total three) cycles of bintrafusp alpha. In the ART-DECO study, which included a similar patient population, more than 80% of patients was able to receive five cycles of carboplatin and paclitaxel (i.e. up to week 5) (personal communication dr. Hulshof). Therefore, the investigators will regard treatment with Bintrafusp alfa during chemoradiation feasible if ≥80% of patients complete two cycles of bintrafusp alfa, while with a completion rate ≤62% the treatment will be regarded unfeasible.

The primary end point of this feasibility study is the percentage of patients completing bintrafusp alfa treatment. This study requires 41 subjects to decide whether the proportion completing at least two cycles of bintrafusp alfa, P, is less than or equal to 0.62 or greater than or equal to 0.80. If the number of patients completing two or more cycles of Bintrafusp alfa is 31 or more, the hypothesis that P ≤ 0.62 is rejected with a target error rate of 0.05 and an actual error rate of 0.048. If the number of patients completing two or more cycles of bintrafusp alfa is 30 or less, the hypothesis that P ≥ 0,80 is rejected with a target error rate of 0.20 and an actual error rate of 0.182. The test statistic used is the one-sided one-sample test for binomial proportion, testing against the fixed reference proportion of 0.62. Taking into account 20% drop-out, 52 patients need to be included in the study.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 52 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: TGF-β And PDL-1 Inhibition in Esophageal Squamous Cell Carcinoma Combined With Chemoradiation TheRapY
Actual Study Start Date : November 30, 2020
Estimated Primary Completion Date : November 1, 2023
Estimated Study Completion Date : November 1, 2028

Arm Intervention/treatment
Adding bintrafusp alfa (a combined TGF-β en PDL-1 inhibitor) to definitive chemoradiation with Paclitaxel and Carboplatin
Combination Product: Bintrafusp alfa
Bintrafusp alfa (M7824, MSB0011359C) is an innovative first-in-class, bifunctional fusion protein composed of the extracellular domain of the human transforming growth factor β receptor II (TGFβRII or TGFβ Trap) covalently linked via a flexible linker to the C-terminus of each heavy chain of an immunoglobulin G1 (IgG1) antibody blocking programmed death ligand 1 (anti-PD-L1). Bintrafusp alfa is the international nonproprietary name for M7824.
Other Name: M7824

Primary Outcome Measures :
  1. Feasibility bintrafusp alfa [ Time Frame: 36 months ]
    The primary endpoint is feasibility defined as percentage completion of treatment with bintrafusp alfa.

Secondary Outcome Measures :
  1. Toxicity according to different criteria [ Time Frame: 36 months ]
    • Incidence and severity of toxicity defined according to CTCAE v5 and Radiation Oncology Group (RTOG) criteria.

  2. Completion of treatment [ Time Frame: 36 months ]
    Percentage completion of chemotherapy and radiation treatment

  3. Progression free survival [ Time Frame: 36 months ]
    Any progression free survival

  4. Survival [ Time Frame: 36 months ]
    Overall survival

  5. QOL [ Time Frame: 36 months ]
    Quality of life, with a special focus on dysphagia

  6. Local progression free survival [ Time Frame: 36 months ]
    Local in-field progression free survival

Other Outcome Measures:
  1. Biomarker development [ Time Frame: 36 months ]
    Potential biomarker development based on assessment of tumour and duodenal biopsies, blood samples and faecal samples

  2. Patient reported outcomes [ Time Frame: 36 months ]
    Patient reported outcomes other than quality of life, including but not limited to anxiety and depression, worry of cancer progression and work productivity.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Histologically proven squamous cell carcinoma of the esophagus or gastro esophageal junction.
  • Surgically irresectable (T1-T4a, N0 or N+, M0), as determined by Endoscopic Ultra Sound (EUS), PET scan and diagnostic CT scan of neck, thorax and abdomen. Patients with M1 disease solely on the basis of supraclavicular metastasis are eligible. Patients with resectable tumors refusing radical surgery or inoperable patients due to comorbidity are eligible.
  • Locoregional recurrences without distant metastasis after surgery alone or endoscopical resection
  • Locoregional recurrences without distant metastasis after neoadjuvant chemoradiation + resection or definitive chemoradiation outside the previously irradiated area, provided that full dose of radiation can safely be delivered.
  • Tumors that cannot be passed with an endoscope for endoscopic ultrasound are eligible if all other criteria are fulfilled.
  • If the tumor extends below the gastroesophageal (GE) junction into the proximal stomach, the bulk of the tumor must involve the esophagus or GE junction.
  • Age ≥ 18.
  • ECOG performance status 0-2 (cf. Appendix A).
  • Adequate hematological, renal and hepatic functions defined as:

    • Neutrophils ≥ 1.5 x 109/L
    • Platelets ≥ 100 x 109/L
    • Hemoglobin ≥ 5.6 mmol
    • Total bilirubin ≤ 1.5 x upper normal limit
    • Creatinine clearance (Cockroft) > 60 ml/min
  • Written, voluntary informed consent
  • Patients must be accessible to management and follow-up in the treatment center

Exclusion Criteria:

  • Past or current history of malignancy other than entry diagnosis interfering with prognosis of esophageal cancer.
  • Patient with tracheo-esophageal fistula or extension into the mucosal layer of the trachea, highly at risk to develop fistula. Thus, tumor extension to the trachea is allowed, but not through the trachea.
  • Patient with aortal involvement with high risk of bleeding or developing a fistula.
  • Patients with pathological lymph nodes at both supraclavicular and truncus coeliacus level.
  • Pregnancy (positive serum pregnancy test), planning to become pregnant, and lactation.
  • Patient (male or female) in the reproductive age is not willing to use highly effective methods of contraception (per institutional standard) during treatment and for 6 months (male or female) after the end of treatment.
  • Previous chemotherapy, radiation and/or treatment with checkpoint inhibitors for the currently present esophageal tumor.
  • Previous chemotherapy and/or treatment with targeted agents and/or checkpoint inhibitors for other forms of cancer within the last six months.
  • Previous radiation to the mediastinum precluding full dose radiation of the currently present esophageal tumor.
  • Presence of an esophageal stent.
  • Clinically significant cardiovascular disease precluding safe treatment with chemoradiation.
  • Evidence of pulmonary fibrosis and/or clinically significant impairment of lung function precluding safe treatment with chemoradiation. In case of doubt about pulmonary function, a lung function test should be performed and, in case of abnormalities, discussed with the principle investigator.
  • Serious underlying medical condition which would impair the ability of the patient to receive the planned treatment, including prior allergic reactions to drugs containing cremophor, such as teniposide or cyclosporine.
  • Mental status that would prohibit the understanding and giving of informed consent.
  • Inadequate caloric- and/or fluid intake despite consultation of a dietician and/or tube feeding.
  • Has an active autoimmune disease that has required systemic treatment in past 2 years (i.e. with use of disease modifying agents, corticosteroids, or immunosuppressive drugs). Replacement therapy (e.g., thyroxine for patients with a history of autoimmune-related hypothyroidism, insulin for patients with type 1 diabetes mellitus, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment. Patients with vitiligo with dermatological manifestations only are eligible to enter the study.
  • A diagnosis of immunodeficiency or is receiving systemic steroid therapy (>10 mg/day prednisone or equivalent) or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatment.
  • Evidence of interstitial lung disease or active, non-infectious pneumonitis.
  • An active infection requiring systemic therapy, which has not resolved 3 days (simple infection such as cystitis) to 7 days (severe infection such as pyelonephritis) prior to the first dose of trial treatment.
  • Patients with prior allogeneic stem cell or solid organ transplantation.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT04595149

Layout table for location contacts
Contact: Hanneke WM van Laarhoven, M.D, PhD 31 20 5665955
Contact: Linde Veen 31 20 5665955

Layout table for location information
Amsterdam UMC Recruiting
Amsterdam, Noord-Holland, Netherlands, 1081HV
Contact: Linde Veen    +31612538338   
Sponsors and Collaborators
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Layout table for investigator information
Principal Investigator: Hanneke WM van Laarhoven, M.D., PhD Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Layout table for additonal information
Responsible Party: H.W.M. van Laarhoven, Head Medical Oncology, Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) Identifier: NCT04595149    
Other Study ID Numbers: Volgt 2
First Posted: October 20, 2020    Key Record Dates
Last Update Posted: January 19, 2021
Last Verified: January 2021

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by H.W.M. van Laarhoven, Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA):
definitive chemoradiation
esophageal cancer
Additional relevant MeSH terms:
Layout table for MeSH terms
Carcinoma, Squamous Cell
Esophageal Squamous Cell Carcinoma
Esophageal Neoplasms
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms, Squamous Cell
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Head and Neck Neoplasms
Digestive System Diseases
Esophageal Diseases
Gastrointestinal Diseases